

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/212489 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) *A61P 29/00* (2006.01)
C07D 407/14 (2006.01) *A61P 3/00* (2006.01)
C07D 409/14 (2006.01) *A61P 35/00* (2006.01)
C07D 417/14 (2006.01) *A61P 37/00* (2006.01)
C07D 213/69 (2006.01) *A61P 43/00* (2006.01)
C07D 213/89 (2006.01) *A61P 9/00* (2006.01)
A61K 31/444 (2006.01) *A61P 9/10* (2006.01)
A61K 31/506 (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

(21) International Application Number:

PCT/US2022/022525

Published:

— *with international search report (Art. 21(3))*

(22) International Filing Date:

30 March 2022 (30.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/168,407 31 March 2021 (31.03.2021) US
63/318,118 09 March 2022 (09.03.2022) US

(71) Applicant: **XINTHERA, INC.** [US/US]; 12730 High Bluff Drive, Suite 300, San Diego, California 92130 (US).

(72) Inventors: **TRZOSS, Lynn**; 12730 High Bluff Drive, San Diego, California 92130 (US). **DONG, Qing**; 12730 High Bluff Drive, San Diego, California 92130 (US). **KALDOR, Stephen W.**; 12730 High Bluff Drive, San Diego, California 92130 (US). **HOFFMAN, Robert L.**; 12730 High Bluff Drive, San Diego, California 92130 (US).

(74) Agent: **BONNEFOUS, Céline**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: MK2 INHIBITORS AND USES THEREOF

(57) Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.



WO 2022/212489 A1